Mavacamten as an Effective Treatment for HCM With Latent Exercise-Induced Obstruction: A Case Report. [PDF]
Murthy N +4 more
europepmc +1 more source
Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy. [PDF]
Ferraresi B +9 more
europepmc +1 more source
Structure-Function Relationship as the Foundation for Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy. [PDF]
Kawana M, Ruppel KM, Spudich JA.
europepmc +1 more source
Knowledge mapping of targeted therapy for hypertrophic cardiomyopathy: A bibliometric analysis of myosin inhibitor research. [PDF]
Liu N +9 more
europepmc +1 more source
Unmasking Latent Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy: Invasive and Noninvasive Assessment. [PDF]
Cho H, Kim J, Lee SC, Choi KH, Yang JH.
europepmc +1 more source
Hemodynamic Implications After Left Ventricular Outflow Tract Obstruction Relief With Mavacamten. [PDF]
Kitai T, Zhang J, Saku K.
europepmc +1 more source
Long-term clinical benefit of mavacamten for hypertrophic cardiomyopathy in a patient with <i>RAF1</i>-associated Noonan syndrome-case report. [PDF]
Seghers HM +4 more
europepmc +1 more source
Obstructive Hypertrophic Cardiomyopathy With Degenerative Mitral Regurgitation: A New Treatment Strategy Using Mavacamten Combined With M-TEER. [PDF]
Wang Y +7 more
europepmc +1 more source

